Inhaled Advantage

Our goal is to deliver inhaled formulations of effective medicines directly to lung tissue, thus enhancing efficacy and avoiding side effects associated with systemic drug delivery.

Optimized for Patient Benefit

Optimized aerosol particle size to reach the diseased tissue in the lungs.
Optimized dose levels that effectively match the drug’s required exposure profile while substantially reducing systemic levels associated with side effects.

Currently, only two oral medicines are available for patients with pulmonary fibrosis. While oral medicines are often convenient for patients, their effectiveness is often limited by significant side effects due to the high doses required. These doses are necessary to overcome inefficiencies of gut absorption, first-pass metabolism, and blood dilution before the medicine reaches the lungs.

Unfortunately, these large doses are likely to amplify side effects to an unacceptable level. Safety concerns related to oral medication levels in the blood prevent achieving the optimal dose needed for effective lung treatment.

THE INHALED PROMISE

By inhalation, small-inhaled doses are delivered directly to the lungs and result in oral-superior lung drug levels that carry potential to improve treatment benefit.

Because these inhaled doses are small, the resulting blood levels following absorption from the lung are well below those following oral delivery. Inhaled therapeutics hold promise to substantially reduce and further improve their potential safety and tolerability profiles compared to the historical data with first-generation oral medicines.

MIST PPF Study now enrolling

Science